NeuBase lays off 60% of employees as it swaps out antisense focus for gene editing tech endorsed by George Church

Amber Tong

Geneticist and serial entrepreneur Dietrich Stephan had hoped that his antisense oligonucleotide platform at NeuBase Therapeutics could expand the field that Ionis pioneered to new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

NeuBase lays off 60% of employees as it swaps out antisense focus for gene editing tech endorsed by George Church

Amber Tong

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

NeuBase lays off 60% of em­ploy­ees as it swaps out an­ti­sense fo­cus for gene edit­ing tech en­dorsed by George Church

Amber Tong

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

NeuBase lays off 60% of employees as it swaps out antisense focus for gene editing tech endorsed by George Church

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?